Lung Cancer Clinical Trials in Pennsylvania

Showing 441-460 of 787 trials

MK-3475 as Maintenance Therapy in Extensive Stage SCLC

NCT02359019

This phase II trial studies how well pembrolizumab works in treating patients with extensive stage small cell lung cancer after completion of combination chemotherapy. Pembrolizumab may be effective in controlling small cell lung cancer for a longer period of time in patients with responsive or stable disease after completion of combination chemotherapy.

Extensive Stage Small Cell Lung Carcinoma

Barbara Ann Karmanos Cancer Institute45 participantsStarted Feb 2015

Chicago, Illinois, United States • Ann Arbor, Michigan, United States • Detroit, Michigan, United States +2 more locations

TERMINATEDPhase 253 miles

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)

NCT04863248

This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 trial evaluating the effect of trilaciclib on overall survival when administered prior to docetaxel in patients with metastatic NSCLC treated in the 2nd or 3rd line setting.

Metastatic Non-Small Cell Lung CancerNSCLCLung Cancer

G1 Therapeutics, Inc.10 participantsStarted Apr 2021

Phoenix, Arizona, United States • Los Angeles, California, United States • Rancho Mirage, California, United States +9 more locations

MK-3475 as Maintenance Therapy in Extensive Stage SCLC

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)

Lung Cancer Trials in Other Cities

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer

Evaluation of GLR2007 for Advanced Solid Tumors

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Safety Study of SEA-CD40 in Cancer Patients

A Chart Review Study of Adults With Advanced NSCLC

A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

Other Conditions in Pennsylvania